Compare PepsiCo, Inc. (PEP) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs GeneDx Holdings Corp — how do they compare? PepsiCo, Inc. trades at $126.28 (market cap $174.89B), while GeneDx Holdings Corp trades at $67.74 (market cap $2.02B). The key difference: PepsiCo, Inc. is far larger — about 86.6× GeneDx Holdings Corp's market cap, and PepsiCo, Inc. pays a 4.61% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold PepsiCo, Inc. for 107 Days and GeneDx Holdings Corp for 19 Days on average.
| PEP | WGS | |
|---|---|---|
Market Cap | $174.89B | $2.02B |
Volume | 23,968,864 | 734,640 |
Sector | Consumer Staples | Health |
52-Week High | $170.44 | $167.51 |
52-Week Low | $123.64 | $34.51 |
Typical Hold Time | 107 Days | 19 Days |
Enterprise Value | $215.61B | $2.05B |
Dividend Yield | 4.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $125.80, up 1.74% today, with a bearish technical signal but strong fundamentals including four consecutive quarterly EPS beats. Revenue grew to $93.93B in 2025, with a net margin of 10.78% and robust cash flow. Analyst consensus is a Buy with a $146.77 price target, though recent news highlights pricing pressures in snacks.
The outlook is mixed: strong profitability and institutional support offer upside, but bearish technicals and consumer pushback on high prices pose near-term risks. Execution on North American turnaround and margin expansion will be critical for sustained growth amid competitive and macroeconomic challenges.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
